Zacks Research Brokers Lower Earnings Estimates for BMY

Bristol-Myers Squibb (NYSE:BMY) – Zacks Research decreased their Q1 2025 earnings estimates for Bristol-Myers Squibb in a research note issued to investors on Thursday, February 20th. Zacks Research analyst E. Bagri now anticipates that the biopharmaceutical company will earn $1.55 per share for the quarter, down from their previous forecast of $1.74. The consensus estimate for Bristol-Myers Squibb’s current full-year earnings is $6.74 per share. Zacks Research also issued estimates for Bristol-Myers Squibb’s Q2 2025 earnings at $1.63 EPS, Q3 2025 earnings at $1.73 EPS, FY2025 earnings at $6.72 EPS, Q1 2026 earnings at $1.34 EPS, Q2 2026 earnings at $1.47 EPS, FY2026 earnings at $5.90 EPS and FY2027 earnings at $6.14 EPS.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, beating analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%.

Several other equities research analysts have also weighed in on the stock. Leerink Partnrs upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 12th. Bank of America reiterated a “neutral” rating and set a $63.00 target price on shares of Bristol-Myers Squibb in a report on Tuesday, December 10th. Truist Financial boosted their target price on Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Citigroup lifted their price objective on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Finally, Wolfe Research assumed coverage on shares of Bristol-Myers Squibb in a research note on Friday, November 15th. They issued a “peer perform” rating on the stock. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, four have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $57.86.

Bristol-Myers Squibb Stock Up 0.1 %

Bristol-Myers Squibb stock opened at $55.85 on Monday. The firm has a market capitalization of $113.33 billion, a price-to-earnings ratio of -12.63, a PEG ratio of 2.07 and a beta of 0.45. The company’s 50 day simple moving average is $56.99 and its 200 day simple moving average is $54.41. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $61.10.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. AMF Tjanstepension AB boosted its stake in shares of Bristol-Myers Squibb by 6.9% during the 3rd quarter. AMF Tjanstepension AB now owns 610,181 shares of the biopharmaceutical company’s stock worth $31,618,000 after acquiring an additional 39,419 shares during the period. Swedbank AB lifted its holdings in Bristol-Myers Squibb by 0.9% during the 3rd quarter. Swedbank AB now owns 3,139,552 shares of the biopharmaceutical company’s stock valued at $162,440,000 after purchasing an additional 28,427 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Bristol-Myers Squibb by 12.7% in the third quarter. Assenagon Asset Management S.A. now owns 64,191 shares of the biopharmaceutical company’s stock valued at $3,321,000 after purchasing an additional 7,245 shares during the last quarter. Mediolanum International Funds Ltd raised its position in shares of Bristol-Myers Squibb by 0.5% in the third quarter. Mediolanum International Funds Ltd now owns 88,527 shares of the biopharmaceutical company’s stock valued at $4,499,000 after purchasing an additional 484 shares during the period. Finally, Pettinga Financial Advisors LLC boosted its holdings in shares of Bristol-Myers Squibb by 8.7% during the 3rd quarter. Pettinga Financial Advisors LLC now owns 11,108 shares of the biopharmaceutical company’s stock worth $575,000 after buying an additional 886 shares during the period. Institutional investors own 76.41% of the company’s stock.

Insider Activity at Bristol-Myers Squibb

In related news, EVP Samit Hirawat acquired 1,823 shares of the business’s stock in a transaction dated Friday, February 14th. The stock was bought at an average price of $54.84 per share, with a total value of $99,973.32. Following the acquisition, the executive vice president now owns 63,932 shares in the company, valued at $3,506,030.88. This represents a 2.94 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.09% of the stock is owned by company insiders.

Bristol-Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were issued a $0.62 dividend. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date was Friday, January 3rd. This represents a $2.48 annualized dividend and a dividend yield of 4.44%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -56.11%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.